MedTrace Logo

Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis

NCT03494205 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-05-27

No results posted yet for this study

Summary

A randomized controlled trial comparing Urtica comp. gel (Swissmedic listed medication in the category of "Anthroposophic Medication without Indication") against standard skin care, examining its effect in prevention and treatment of radiation dermatitis in breast cancer patients under Radiation therapy.

Conditions

  • Radiation Dermatitis

Interventions

DRUG

Urtica comp. gel

Urtica comp. gel is a Swissmedic registered medication. The scope of application of Urtica comp. is an imbalanced, affected process of skin-regeneration, in particular when stemming from an overdose of heat or light. It is applied in first and second-degree burn and scalding, sunburn, allergic and hyperergic (excessive) skin conditions (dermatoses), insect bites, abrasions and ulcers.

DRUG

institutional standard skin care "Excipial-Hydrolotion"

The institutional standard skin care "Excipial-Hydrolotion" is available to all patients

Sponsors & Collaborators

  • University of Bern

    lead OTHER

Principal Investigators

  • Ursula Wolf · University Bern, Institution of Complementary Medicine

  • Nikola Cihoric, MD PhD · University Bern, Department of Radiation Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-02
Primary Completion
2022-02-10
Completion
2022-02-10

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03494205 on ClinicalTrials.gov